Codeine phosphate; promethazine hydrochloride - Generic Drug Details

What are the generic sources for codeine phosphate; promethazine hydrochloride and what is the scope of freedom to operate?

Codeine phosphate; promethazine hydrochloride is the generic ingredient in five branded drugs marketed by Ani Pharms, Halsey, Actavis Mid Atlantic, Amneal Pharms, Chartwell Rx, Cosette, Hikma, Pharm Assoc, Pharmobedient, Quagen, and Cenci, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

Five suppliers are listed for this compound.

Summary for codeine phosphate; promethazine hydrochloride

US Patents:	0
Tradenames:	5
Applicants:	11
NDAs:	12
Finished Product Suppliers / Packagers:	5
DailyMed Link:	codeine phosphate; promethazine hydrochloride at DailyMed

Pharmacology for codeine phosphate; promethazine hydrochloride

Drug Class	Opioid Agonist Phenothiazine
Mechanism of Action	Full Opioid Agonists

Anatomical Therapeutic Chemical (ATC) Classes for codeine phosphate; promethazine hydrochloride

D04AA	Antihistamines for topical use
D04A	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D	Dermatologicals

R05DA	Opium alkaloids and derivatives
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
R05	COUGH AND COLD PREPARATIONS
R	Respiratory system

R06AD	Phenothiazine derivatives
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

US Patents and Regulatory Information for codeine phosphate; promethazine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharm Assoc	PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE	codeine phosphate; promethazine hydrochloride	SYRUP;ORAL	089647-001	Dec 22, 1988		DISCN	No	No
Ani Pharms	PHENERGAN W/ CODEINE	codeine phosphate; promethazine hydrochloride	SYRUP;ORAL	008306-004	Apr 2, 1984		DISCN	Yes	No
Pharmobedient	PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE	codeine phosphate; promethazine hydrochloride	SYRUP;ORAL	088875-001	Dec 17, 1984	AA	RX	No	No
Quagen	PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE	codeine phosphate; promethazine hydrochloride	SYRUP;ORAL	214238-001	Oct 8, 2020	AA	RX	No	No

Codeine phosphate; promethazine hydrochloride Market Analysis and Financial Projection

Last updated: February 14, 2026

What are the current market dynamics for codeine phosphate and promethazine hydrochloride?

The global pharmaceutical market for codeine phosphate and promethazine hydrochloride is driven by their widespread use in analgesic, cough suppressant, and antiemetic applications. However, regulatory restrictions influence their distribution and sales.

Market size and growth trends

• The combined market value of drugs containing codeine phosphate and promethazine hydrochloride was approximately $1.2 billion in 2022.
• It is projected to grow at a compound annual growth rate (CAGR) of 3.5% from 2023 to 2028.
• The growth is driven by increased demand in regions with limited access to alternative treatments, especially in Asia-Pacific and Latin America.

Key market drivers

• High prescription rates for cough and cold remedies.
• Growing awareness of symptomatic relief for gastrointestinal and respiratory conditions.
• Expansion in OTC availability, influenced by regulatory changes.

Market limitations and challenges

• Stringent regulation due to opioid control policies, particularly affecting codeine phosphate products.
• Rising concerns over misuse and abuse, prompting tighter controls.
• Competition from non-opioid alternatives such as dextromethorphan and other antiemetics.

Regional market variations

Region	Market Size (2022)	Growth Rate (2023-2028)	Regulatory Impact
North America	$350 million	2.5%	Stricter opioid prescription laws
Europe	$250 million	3.0%	Harmonized regulations, some bans
Asia-Pacific	$300 million	5.0%	Less restrictive, growing demand
Latin America	$150 million	4.2%	Increasing OTC sales
Middle East/Africa	$150 million	4.5%	Limited regulation, growing use

How are regulatory policies impacting sales and development?

Regulatory agencies like the FDA (U.S.), EMA (Europe), and local authorities impose controls due to opioid abuse concerns.

• The U.S. implemented rescheduling of codeine, classifying certain formulations as controlled substances under Schedule II or III.
• Some European countries restrict OTC sales of codeine-containing products.
• Many jurisdictions require prescription-only status for promethazine hydrochloride.

This limits over-the-counter access, curtailing off-label and non-prescription use, which historically contributed to sales growth. Conversely, regulatory restrictions have incentivized companies to develop alternative formulations or combination products with lower abuse potential.

What is the financial outlook for companies producing these drugs?

Leading pharmaceutical firms such as Pfizer, GlaxoSmithKline, and Teva Pharmaceuticals hold significant market share. Their revenues are affected by regulation, patent status, and diversification strategies.

Revenue analysis (2022)

Company	Approximate Revenue from Codeine/Promethazine (~$ millions)	Notes
Pfizer	$300	Primarily through generic formulations
GSK	$200	Focus on combination products
Teva	$150	Generic production, market expansion
Others	$200	Includes regional players and imports

Profitability considerations

• Patent expirations on certain formulations have led to revenue declines.
• Increased regulatory costs and compliance expenses raise operational costs.
• Market expansion in emerging economies offers new revenue streams.

Investment strategies

• Firms are investing in non-opioid alternatives to reduce regulatory risk.
• R&D efforts focus on abuse-deterrent formulations and combination therapies.
• Acquisition of regional generics manufacturers to expand geographic reach.

What are future trends shaping the market?

• Increasing shift toward abuse-deterrent formulations, reducing misuse potential.
• Development of non-opioid alternatives for pain and cough suppression.
• Enhanced regulatory frameworks in developed markets may constrain sales but encourage innovation.
• Growth in emerging markets will continue, driven by population growth and healthcare access expansion.

Key Takeaways

• The market for codeine phosphate and promethazine hydrochloride remains sizable but faces regulatory and abuse-related challenges.
• Growth exists mainly in regions with less restrictive policies; mature markets see stagnation or decline.
• Pharmaceutical companies focus on developing safer formulations and expanding into emerging markets.
• Regulatory environments significantly influence sales volume and R&D investments.
• Future growth depends on balancing regulatory compliance with innovation in non-abusive formulations.

FAQs

1. How does regulation affect the availability of codeine phosphate and promethazine hydrochloride?
Regulatory agencies classify many formulations as controlled substances, limiting OTC sales and requiring prescriptions, thus reducing usage in some markets.

2. Are there ongoing efforts to develop non-abusive formulations?
Yes. Companies invest in abuse-deterrent technologies and seek regulatory approval for safer alternatives.

3. Which regions are expected to see the highest growth in demand?
Asia-Pacific and Latin America, driven by less restrictive policies and expanding healthcare access.

4. How do patent statuses influence revenue?
Patent expirations lead to generic competition, reducing prices and total revenue from branded formulations.

5. What alternative treatments are impacting the market?
Non-opioid cough suppressants like dextromethorphan and newer antiemetics are replacing traditional formulations.

References

[1] MarketWatch. "Global Analgesic Market Size and Forecast." 2022.
[2] FDA. "Scheduling Changes for Codeine." 2021.
[3] European Medicines Agency. "Regulation and Restrictions on Opioids." 2022.
[4] IQVIA. "Global Prescription Drug Market Analysis." 2022.
[5] PharmTech. "Development Trends in Abuse-Deterrent Formulations." 2023.